Drug Trial Radar · NCT04686305
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
304
Planned (sponsor's estimate)
Start
Mar 9, 2021
Primary completion
Jun 30, 2027
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Daiichi Sankyo
- First posted
- Dec 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
DESTINY-Lung03 will investigate the safety and tolerability of trastuzumab deruxtecan in combination with Immunotherapy Agents with and without chemotherapy in patients with HER2 over-expressing non-small cell lung cancer. The efficacy will be also analyzed as a secondary endpoint.
Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Interventions
T-DXdDrug
T-DXd: administered as an IV infusion
DurvalumabBiological
Durvalumab: administered as an IV infusion
CisplatinDrug
Cisplatin: administered as an IV infusion
CarboplatinDrug
Carboplatin: administered as an IV infusion
PemetrexedDrug
Pemetrexed: administered as an IV infusion (drug not used)
VolrustomigDrug
Volrustomig: administered as an IV infusion
RilvegostomigDrug
Rilvegostomig: administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of AEs and SAEsTime frame: Safety and tolerability (and to determine RP2D) will be assessed for approximately 20 months from informed consent
Locations
91 sites in 19 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Withdrawn
Research Site
Newport Beach, California · Withdrawn
Research Site
Orange, California · Recruiting
Research Site
Santa Rosa, California · Withdrawn
Research Site
Westwood, Kansas · Withdrawn
Research Site
Baltimore, Maryland · Recruiting
Research Site
Detroit, Michigan · Withdrawn
Research Site
Buffalo, New York · Withdrawn
Research Site
New York, New York · Withdrawn
Research Site
The Bronx, New York · Withdrawn
Research Site
Houston, Texas · Recruiting
Research Site
Fairfax, Virginia · Recruiting
Research Site
Tacoma, Washington · Withdrawn
Research Site
Adelaide, Australia · Terminated
Research Site
Heidelberg, Australia · Withdrawn
Research Site
Nedlands, Australia · Recruiting
Research Site
Edegem, Belgium · Completed
Research Site
Barretos, Brazil · Recruiting
Research Site
Porto Alegre, Brazil · Recruiting
Research Site
São Paulo, Brazil · Recruiting
Research Site
Winnipeg, Manitoba, Canada · Withdrawn
Research Site
London, Ontario, Canada · Withdrawn
Research Site
Montreal, Quebec, Canada · Recruiting
Research Site
Changchun, China · Not yet recruiting
Research Site
Chengdu, China · Not yet recruiting
Research Site
Fuzhou, China · Not yet recruiting
Research Site
Shandong, China · Not yet recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Zhengzhou, China · Not yet recruiting
Research Site
Bordeaux, France · Withdrawn
Research Site
Dijon, France · Recruiting
Research Site
Pierre-Bénite, France · Recruiting
Research Site
Saint-Herblain, France · Recruiting
Research Site
Villejuif, France · Recruiting
Research Site
Kfar Saba, Israel · Recruiting
Research Site
Tel HaShomer, Israel · Recruiting
Research Site
Milan, Italy · Completed
Research Site
Milan, Italy · Recruiting
Research Site
Monza, Italy · Recruiting
Research Site
Naples, Italy · Recruiting
Showing 40 of 91 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.